Icosapent ethyl

二十碳五烯酸乙酯

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameIcosapent ethyl
Drug Alias Name顺-二十碳五烯酸乙酯Ethyl eicosapentaenoic acid二十烷五烯酸乙酯Eicosapentaenoic acid ethyl esterIcosapent ethyl ester +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Large intestine neoplasmSchizophrenia +[26] 
Global Approved IndicationsHypertriglyceridemiaHyperlipidemiasDyslipidemias +[5] 
Approved Indications in ChinaHypertriglyceridemia
Original Approved Country/TerritoryJapan
Original Approved Date1998/07/01
Country/TerritoryCanadaUnited StatesUkraine +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesScarista Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNippon Zoki Pharmaceutical Co LtdNational Institutes Of HealthPfizer Inc +[13] 
Inactive CompaniesThe Brigham and Women's HospitalHarvard School Of Public HealthNational Center For Complementary And Integrative Health +[15] 
Active IndicationsLarge intestine neoplasmInflammationHypertriglyceridemia +[11] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)SchizophreniaDepressive Disorder, Major +[15] 

Other Information

ATC CodeC10AX
Related LinksWikipediaDrugBankKEGG